November 2019 Vol 12, No 7

The Economic Implications of Hyperkalemia in a Medicaid Managed Care Population

Nihar R. Desai, MD, MPH; Pamala Reed, DrPH, MPH; Paula J. Alvarez, RPh, MBA, MPH; Jeanene Fogli, PhD, RD; Steven D. Woods, PharmD; Mary Kay Owens, RPh, CPh

Stakeholder Perspective

The Impact of Quality Care on a Medicaid Population with Hyperkalemia

Byron C. Scott, MD, MBA

FDA Approvals

FDA Oncology Update

Editorial

Predicting Success in Population Health

David B. Nash, MD, MBA

Business, Original Research

Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia

David Campbell, PharmD, MS; Marlo Blazer, PharmD, BCOP; Lisa Bloudek, PharmD, MS; John Brokars, MS; Dinara Makenbaeva, MD, MBA

Stakeholder Perspective

The Challenges in Budgeting Potential Savings with the Launch of Generic Drugs

James T. Kenney, RPh, MBA

Industry Trends

Key Trends in Healthcare for 2020 and Beyond

F. Randy Vogenberg, PhD; John Santilli, MBA

Results 1 - 5 of 5

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Print Edition

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.